Amphastar Pharmaceuticals (AMPH) Income towards Parent Company (2013 - 2026)

Amphastar Pharmaceuticals' Income towards Parent Company history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 74.61% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at -$49.7 million (down 133.82% YoY), while the FY2025 annual figure was -$30.9 million, down 118.64% from the prior year.
• Income towards Parent Company was $6.4 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$104.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $49.6 million in Q3 2023 to a low of -$104.5 million in Q4 2025.
• Historically, Income towards Parent Company has averaged $22.0 million across 5 years, with a median of $26.8 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company soared 530.36% in 2022, then plunged 340.96% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at $34.0 million in 2022, then gained by 7.95% to $36.7 million in 2023, then gained by 18.29% to $43.4 million in 2024, then slumped by 340.96% to -$104.5 million in 2025, then jumped by 106.14% to $6.4 million in 2026.
• The last three Income towards Parent Company figures came in at $6.4 million (Q1 2026), -$104.5 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.